Skip to main content
. 2015 Jul 23;5:12371. doi: 10.1038/srep12371

Figure 2. The protective role of the individual immunodominant SEB epitopes against MRSA252 challenge.

Figure 2

(A) Percent survival in mice immunised with individual epitopes plus AlPO4 or CFA/IFA adjuvant, AlPO4 or CFA/IFA adjuvant alone, or PBS alone. The significance of protective immunity generated by the individual epitope vaccine was measured with Fisher’s exact test: : for CFA/IFA adjuvanted vaccine, SEB31–48-KLH (P = 0.011), SEB97–114-KLH (P = 0.011), SEB133–150-KLH (P = 0.033), SEB193–210-KLH (P = 0.003), SEB205–222-KLH (P = 0.087) SEB247–261-KLH (P = 0.033); for AlPO4 adjuvanted vaccine, SEB31–48-KLH (P = 0.033), SEB97–114-KLH (P = 0.087), SEB133–150-KLH (P = 0.033), SEB193–210-KLH (P = 0.011), SEB205–222-KLH (P = 0.087), SEB247–261-KLH (P = 0.087). (B) Antibody production of Polypeptides or the individual immunodominant epitope -vaccinated mice. ELISA detection of the individual immunodominant epitope specific antibody levels in mice immunised by the individual immunodominant epitope. (C) ELISA detection of Polypeptides specific antibody subtype in mice immunised with the individual epitopes. IgG subclass distribution in mice immunised with different formulations. Results are representative of three experiments and data are mean ± SD of samples from ten mice. (D) ELISA detection of SEB specific antibody subtype in mice immunised with the individual epitopes. IgG subclass distribution in mice immunised with different formulations. Results are representative of three experiments and data are mean ± SD of samples from ten mice.